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Introduction 
Alzheimer’s Disease (AD) is the most common type of dementia in the elderly, being a severe neurodegenerative disorder characterized by cognitive impairment and 
behaviour changes.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objectives 
 
• Analyse current diagnosis of the disease: emphasize  the need of less invasive biomarkers.  
• Establish what is a biomarker and how should be an ideal biomarker for AD 
• Describe biomarkers studied in blood cells and skin fibroblasts 
• Summarize biomarkers found in plasma. 
• Mention the use of miRNAs as potential biomarkers for AD 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methods 
 
The project has been made as a scientific review using the bibliography obtained from Pubmed 
Database and Scopus. At first, the search was focused on reviews containing the keywords 
biomarkers, Alzheimer’s disease, peripheral, blood, fibroblast, miRNA, among others. Then, the 
information provided by these papers allowed further searches in order to find more specifical 
original articles. Papers used have been published mainly between 2010 and 2015 in journals 
classified in Q1 or Q2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• The present situation points to a promising future for this field: novel approaches are emerging continuously. The view of AD as a disease not limited 
to the brain has made easier the detection of potential biomarkers in peripheral tissues such as blood or skin fibroblasts.  
 
• Results obtained until now show a wide range of abnormalities related to AD that would serve as biomarkers of the disease. Nevertheless, in some 
cases there is controversy between studies and in other cases replication and validation is needed. 
 
• In fact, as none of the individual markers is powerful enough to be applied in routine AD diagnosis, it may be useful to employ combinations of them, in 
order to achieve high levels of sensitivity and specificity.  
 
• Henceforth it is essential to reach a harmonization of protocols, incorporate methods of validation and start larger studies in order to accomplish a 
non-invasive AD diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarkers of Alzheimer’s Disease From Peripheral Tissue 
  
A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention.  An 
ideal AD biomarker should: 
1) Detect fundamental neuropathological hallmarks  
2) Differentiate AD from non-AD dementias 
3) Recognize early stages and distinguish the progression of AD 
4) Be easy to perform and inexpensive 
5) Use minimally invasive sample collection 
6) Be highly reliable, with high levels of sensitivity and specificity 
 
 
Cerebrospinal 
fluid biomarkers 
(CSF) 
Aβ 1-42 
Total tau 
Phosphorylated 
tau 181 
Neuroimaging 
approaches 
Magnetic ressonance 
imaging 
Amyloid tracer 
imaging 
18C-fluorodeoxyglucose 
uptake 
Stablished and validated 
 
Too expensive 
 
CSF collection implies an invasive 
procedure  
 
 
 
  
Impractical for initial diagnosis  
or routine screenings 
Conclusions 
 
[1] Canobbio I, Abubaker AA, Visconte C, Torti M, Pula G. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in 
Alzheimer’s disease. Front Cell Neurosci.2015;9:65 
 
[2] Femminella GD, Ferrara N, Rengo G. The emerging role of microRNAs in Alzheimer’s disease. Front Physiol. 2015;6:40. 
 
[3] Henriksen K, E. O’Bryant S, Hampel H, Q. Trojanowski J, Al. E. The future of blood-based biomarkers for Alzheimer’s disease. 
Alzheimers Dement. 2014;10(1):115–31. 
 
[4] Khan TK, Alkon DL. Peripheral Biomarkers of Alzheimer’s Disease. J Alzheimers Dis . 2015;44(3):729–44. 
 
[5]Thambisetty M, Lovestone S. Blood-based biomarker of Alzheimer’s disease: challenging but feasible. Biomark Med. 2010;4(1):65–
79. 
 
[6] Veitinger M, Varga B, Guterres SB, Zellner M. Platelets, a reliable source for peripheral Alzheimer’s disease biomarkers? Acta 
Neuropathol Commun. 2014 Jan;2:65.  
 
 
 
 
 
 
 
 
References 
Pathological hallmarks of AD include synaptic and neuronal loss, astrocytosis, intraneuronal inclusions of 
hyperphosphorilated tau protein in neurofibrillary tangles (NFT) and extracellular deposits of amyloid β (Aβ), also called senile 
plaques. Aβ is synthesized from β -amyloid precursor protein (APP), which can be cleaved by two proteolytic pathways: the 
non-amyloidogenic pathway and the amyloidogenic pathway (which generates Aβ peptides) (Fig. 1). Disruptions in Aβ clearance 
and/or production results in their accumulation in brain and blood vessels. 
 
There are two main types of AD: early-onset (or familial), which develops before 65 years and is a rare autosomal dominant 
disease caused by mutations in APP or presenillin genes; and late-onset (or sporadic), that occurs late in life and is a 
predominant multifactorial and heterogeneous disease.  
 
 
 
miRNA Role in AD pathophysiology Evidence in AD patients 
miR-9 Involved in neurogenesis and cell 
survival during brain development.  
Downregulated in serum of AD patients. 
miR-107 Negative correlation with BACE1 and 
neuritic plaque density; targets BACE1, 
CDK5 and ADAM10 
Downregulated in temporal cortex and 
serum of AD patients 
miR-29 Inversely correlated with BACE1; it has 
been shown to increase amyloid 
production in vitro 
Downregulation in human AD temporal 
cortex, cerebellum and serum.  
miR-34 Regulates the expression of p53 Higher expression in the hippocampus of 
patients with AD 
miR-181 Aβ is able to downregulate miR-181 
expression in vitro; regulates SIRT1 
expression  
Downregulated in human temporal cortex 
and patient serum 
miR-106 Directly bind to APP mRNA; can also 
regulate the expression of the 
transporter ABCA1, which is involved in 
ApoE production. 
Downregulated in temporal cortex of AD 
patients 
miR-146a Regulator of inflammation-related 
mRNA acts as an inflammatory 
response repressor in the CNS 
“Selective” upregulation in brain regions 
affected by AD pathology, such as 
temporal cortex and hippocampus. 
miR-155 Appears to have specific effects on 
complement factor H (ICFH) down-
regulation in neurodegenerative brain 
Upregulated in Down’s syndrome (AD-
like neuropathology with age) 
miR223* Seems to have a neuroprotective effect Downregulated in serum of AD patients. 
Suggested as a neurodegenerative 
biomarker.  
miR-125b* Brain-enriched miRNA abundantly 
expressed in AD neocortex.    
Downregulated in serum from patients 
with AD. 
* Data from Galimberti et al (2014)  
Blood-based biomarkers 
Skin Fibroblast-based biomarkers 
miRNA as AD biomarkers 
 
Simple and inexpensive 
 
Easy to culture fibroblasts without contamination 
 
It’s possible to repeat experiments 
 
Detect signaling disruptions      
 
                      Early diagnosis 
 
Slow growth in culture  
 
      Biopsy                    Test results 
 

 


 
Plasma-based biomarkers 
Proteomics 
Plasma protein profiles or single candidate proteins, 
including homocysteine, C reactive protein, cytokines, 
chemokines, apolipoproteins and growth factors.  
 
       Lack of replication and standardization 
       Variability and complexity of blood proteome 
Lipidomics 
Alterations in lipid pathways related to AD. Some of the 
most studied are: 
  Ceramide/sphingomyelin ratio  
  Abnormal glycerophospholipids 
  Abnormal lipid peroxidation  
  Lower desmosterol /cholesterol ratio 
Plasma Aβ species 
Results obtained are not clear, probably by reason of: 
  Plasma Aβ = brain Aβ + peripheral tissues Aβ  
  Blood brain barrier can be altered in AD 
  Aβ tends to bind to plasma proteins and test tube walls 
Blood cell-based biomarkers 
Platelets 
Are the first peripheral source of APP, 
containing secretase proteolytic machinery.  
  sAPPα>>Aβ:  α-secretase activity  
Erythrocytes 
  Alteration of PKC conformation 
Leucocytes 
   GSK-3 
  Alteration of PKC conformation      
(lymphocytes) 
  
  
stored in α granules and 
released upon stimulation  
Regulation of hemostasis (Fig. 2) 
Fig 2. Platelet activation induced by Aβ peptides. From Canobbio et al (2015) 
Fig 1. APP cab be cleaved by β-γ- secretases,  releasing 
Aβ peptides or by α-γ-secretases. From Canobbio et al 
(2015)  
Molecular signaling abnormalities  arise at early stages 
 
Easy and minimally invasive  collection 
 
Processing of blood cells is more complex and time-consuming  
PKCε deficit 
 
 
 
 
 
 
 
 
  
 

Altered APP ratio 

120−130kDa APP
110kDa APP
     correlated with AD 
progression, including early stages. 
Altered secretase activity 
 
       
Enhanced platelet activation 
 coated platelets      early stages 
                                  
                                     
 α-secretase 
 
  β-secretase 
 
  Aβ secretion 
 
 clot formation  
 fibrinolysis  
 clotting factors 
 
 
Challenges of Blood-based biomarkers 
Currently there are no fully validated blood-based biomarkers, owing to… 
 Failure to replicate findings due to the high variability between studies 
 Interferences with the multiple conditions that affect elderly people 
 
Fig 3. An.overview of PKCε and Erk1/2 
signaling cascade. Adapted from Thomson 
Reuters 
Erk 1/2 phosphorilation in response to bradykinin (Fig. 3)  
        AD index =
P − Erk1
P − Erk2
BK+
− 
P − Erk1
P − Erk2
BK−
 
 
Could distinguish:  
 AD/controls   
 AD/ non-AD dementias 
Inversely correlated with AD progress 
 
 
SciencePhotoLibrary. Fibroblast cells 
[Internet]. 2015. Available from: 
http://www.sciencephoto.com/media/1
88383/view 
 
 PKCε in the brains of AD patients 
PKCε 
 Aβ peptides cause PKCε 
PKCε  in skin fibroblast from AD 
patients in correlation with disease 
progression  
Positive value in AD patients 
Ca2+ imaging 
 
Calcium 
dysregulation 
Disruption in 
amyloid β and tau 
production  
Observed in  
AD brain and  
skin fibroblasts 
 
 
Huge variability between studies of Ca2+-based bioassays 
 
     Cytoplasmic ionic Ca2+ levels 
 
     TEA (K+ channel blocker) 
 
     Bradykinin (Fig. 3) 
  
 
 
 
 
Fibroblasts aggregation rate 
Elevated aggregation rate and increasing cell 
density in AD fibroblasts 
 
Promising but very recent: further research is needed 
Enhanced PKCε activity Aβ levels 
No significant breakthroughs done in recent years 
Novel approach that has to be  
replicated in larger studies 
PKCε activation prevents synaptic  
loss and  memory deficits in AD mice 
 
Fig 4. Mechanism of action of miRNAs.From 
Mpietrangelo.com. 2009 . Available from: 
http://www.mpietrangelo.com/hbio/unit/8_genetics/Chapter_
11/B_Jpegs_of_Art_and_Photos/11_Labeled_Art_and_Photos
/11_07microRNAs-L.jpg  
miRNAs (microRNAs) are small coding RNAs 
that act as regulatory modulators of gene 
expression by two main mechanisms of action 
(Fig 4)  
Specific miRNAs are expressed in the CNS 
neuronal 
differentiation 
synaptic 
plasticity 
neurite 
outgrowth 
miRNA dysregulation seems to be involved in 
neurodegenerative processes, such as AD(Table 1) 
Blood CSF Brain 
Impractical     suitable for clinical diagnosis  
Table 1. Some of the most common miRNA related to AD. Adapted from Femminella et al (2015) 
 
 Extensive validation and follow-up studies are required, in order to ensure their 
potentiality. 
 Circulating miRNAs may be the next generation of promising biomarkers for AD, 
alone or in combination with other biomarkers 
Will miRNA be used in the future for AD diagnosis? 
correlated with AD progress 
Definitive AD diagnosis is restricted to 
postmortem evaluation of senile 
plaques and neurofibrillary tangles in 
the brain 
Currently, AD diagnosis is 
restricted to 
neuropsycological tests 
and brain imaging 
The identification of potential 
biomarkers is required to 
achieve an early and specific 
diagnosis. 
Clinical diagnosis of AD is unreliable, particularly: 
• During early stages of the disease 
• When it presents with other dementias 
 
